Phytosterols: From Preclinical Evidence to Potential Clinical Applications

Bahare Salehi1, Cristina Quispe2, Javad Sharifi-Rad3,4*, Natália Cruz-Martins5,6,7, Manisha Nigam8, Abhay Prakash Mishra9, Dmitry Alexeevich Konovalov10, Valeriya Orobinskaya11, Ibrahim M. Abu-Reidah12, Wissam Zam13*, Farukh Sharopov14*, Tommaso Venneri15, Raffaele Capasso16, Virgínia Kukula-Koch17, Anna Wawruszak18 and Wojciech Koch19*

OPEN ACCESS

Edited by: Marcello Locatelli, University of Studies G. d’Annunzio Chieti and Pescara, Italy
Reviewed by: Antonio Cilla, University of Valencia, Spain and Magdalena Rudzińska, Poznan University of Life Sciences, Poland

*Correspondence:
Javad Sharifi-Rad javad.sharifiRad@gmail.com
Wissam Zam
ws.sarah2005@gmail.com
Farukh Sharopov shfarukh@mail.ru
Wojciech Koch
kochwi@intenia.pl

REVIEW

published: 14 January 2021
doi: 10.3389/fphar.2020.599959

INTRODUCTION

Phytosterols (PSs) are plant-originated steroids. Over 250 PSs have been isolated, and each plant species contains a characteristic phytosterol composition. A wide number of studies have reported remarkable pharmacological effects of PSs, acting as chemopreventive, anti-inflammatory, antioxidant, anti-diabetic, and anti-atherosclerotic agents. However, PS bioavailability is a key issue, as it can be influenced by several factors (type, source, processing, preparation, delivery method, food matrix, dose, time of administration into the body, and genetic factors), and the existence of a close relationship between their chemical structures (e.g., saturation degree and side-chain length) and low absorption rates has been stated. In this sense, the present review intends to provide in-depth data on PS therapeutic potential for human health, also emphasizing their preclinical effects and bioavailability-related issues.

Keywords: phytosterols, β-sitosterol, campesterol, low-density lipoprotein cholesterol, coronary heart disease

Consumer awareness for healthy lifestyles, seeking optimal health and longevity, has moved primary attention toward nutrition that offers health potentialities beyond staple food. In fact, bioactive-rich diets at appropriate amounts are invaluable for health maintenance (Floros et al., 2010), where the impact of a balanced diet is crucial. Often conceived as providing a proper variety of distinct types of food and concomitantly adequate amounts of the required nutrients to ensure good health and
Although PS are found in all plant foods (Shari et al., 2015), with more than 250 PS being recognized so far. They are also good dietary sources of PS (Shari et al., 2018). Nuts, seeds, whole grains, and legumes are good sources; however, nuts, seeds, whole grains, and legumes are good sources as well. Soybeans, peas, macadamia, and almonds are extremely rich in PS (Piironen et al., 2003; Wadikar et al., 2017). They are classified into sterols and stanols, representing the unsaturated and saturated molecules, respectively (Piironen et al., 2000). Beta-sitosterol, 4 of 47 campesterol, and stigmasterol (Figure 2) are the most common plant–derived sterols in human diet. All contain a core skeleton of cholesterol but possess a different side chain. Betasitosterol and stigmasterol have an ethyl group at C-24, whereas campesterol is equipped with a C24-methyl group. Stigmasterol derives from sitosterol by the action of sterol C-22 desaturases. Brassicasterol, and D-7-avenasterol are minor constituents. Stanols are also found in plants, although they form only 10% of total dietary phytosterol (PS) (Jones and AbuMweis, 2009). Briefly, PSs are biologically active molecules with multiple health applications, and increasing evidence has shown that PS activity depends on various criteria, such as formulation and solubility in the food matrix (Schiepers et al., 2009; Poudel et al., 2019). Nonetheless, as humans cannot synthetize PSs, they should obtain them from diet (Cabral and Klein, 2017).

There is increasing scientific evidence supporting the idea that PSs and their derivatives have multiple pharmacological properties, including human-wellness-promoting abilities. These health benefits include a great ability to reduce total and low-density lipoprotein (LDL) cholesterol levels, thus decreasing the risk of many diseases (Plat et al., 2019). Moreover, PSs also modulate inflammation; have antioxidant, antiulcer, immunomodulatory, antibacterial, and antifungal effects; and also intervene in wound healing promotion and platelet aggregation inhibition (Dutta, 2003; Ogbe et al., 2015).

To what concerns to PS health effects and given its long history of safe consumption, they have been targeted of an increasingly specific and highly regulated labeling to ensure consumers protection and safety. So far, the authorized health claims for PS consumption, when consumed as part of a healthy diet and lifestyle, are directly related to its ability to help maintain or reduce the low-density lipoprotein cholesterol (LDL-C) level, with marked reductions in blood cholesterol of 7–12.5% for intakes of 1.5–3 g/day (Shortt, 2015). In addition, issues related to plant sterols and stanols safety have already been declared by international agencies, such as the Food and Drug Administration (FDA) and the European Union Scientific Committee (EUSC) (Dutta, 2003), which clearly reveals their promissory potential at the same time that denotes the huge attention paid to this class of biomolecules.

In this sense, the present review is aimed at providing detailed information on PS therapeutic potential for human health, moving from preclinical to clinical pharmacological effects, and bioavailability issues.

**PRECLINICAL PHARMACOLOGICAL ACTIVITIES OF PHYTOSTEROLS**

Experiments in animals and cell manners have shown that PSs may confer a wide number of biological effects, including chemopreventive, antioxidant, anti-inflammatory, anti-diabetic, anti-atherosclerotic, and cardioprotective agents (Table 1).

**Chemopreventive Effects**

Several studies have reported that PSs possess anticancer properties through interaction with various cell targets and pathways.

Beta-sitosterol isolated from *Asclepias curassavica* L. was reported to be effective in colorectal cancer in a dose-related
approach. β-sitosterol supplementation decreased the number of aberrant crypts and crypt multiplicities in 1,2 dimethylhydrazine (DMH)-initiated rats without exerting toxic effects and also attenuated β-catenin and proliferating cell nuclear antigen (PCNA) expression in human intestinal carcinoma cells (Baskar et al., 2010). Various experiments have also revealed that β-sitosterol supplementation is effective in MCF-7 and MDA-MB-231 breast cancer cells, triggering apoptosis by increasing Fas protein expression, caspase 8, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (Daniel et al., 2001; Awad et al., 2007; Herbst et al., 2010). Awad et al. (2000) observed that β-sitosterol stimulated apoptosis in MDA-MB-231 cells and reduced tumor size through an estrogen-signaling-independent process. In another study, dietary PS supplementation decreased mammary hyperplastic lesions and total tumor burden in female mice fed with a high-fat diet but not in those with a low-fat diet. This was partly explained by the preventative lipoprotein oxidation/inflammation properties of PSs, which was found to be crucial for tumor expansion (Llaverias et al., 2013). β-sitosterol and daucosterol identified in Grewia tiliacolia, alone or in combination, had the potential to promote apoptotic death of A549 lung cancer cells by arresting the cell cycle at the G2/M phase (Rajavel et al., 2017). β-sitosterol was also found to significantly induce cell viability reduction in cervical cancer cells (HeLa) in a dose-related approach, interfering on DNA fragmentation through the appearance of a sub-G1 cell population (Alvarez-Sala et al., 2019). Cilla and colleagues (Cilla et al., 2015) in a study performed on Caco-2 cells stated that PSs and β-Cx, used alone or combined, markedly decreased cell viability through mitochondrial pathway-induced apoptosis. As main triggers, the authors reported BAD dephosphorylation, mitochondrial depolarization, and caspase 3-dependent PARP cleavage, along with intracellular Ca²⁺ influx and ROS level raise. Similar findings were stated by López-García and colleagues (López-García et al., 2017), who found that PSs trigger cell cycle arrest in phase G0/G1 and cell necrosis in Caco-2 cells. In a similar way, Alvarez-Sala and colleagues (Alvarez-Sala et al., 2018a), addressing the PS impact in colon cancer cells (Caco-2 and HT-29 cell lines) used in combination with 5-fluorouracil, stated a pronounced cell cycle arrest at S phase, induction of apoptosis, and rise in caspases activation.

**Antioxidant and Anti-Inflammatory Activities**

Several reports have indicated that PSs possess interesting antioxidant and anti-inflammatory effects. *In vitro* studies indicated that PSs reduced lipid peroxidation in platelet membranes in the presence of iron (Van Rensburg et al., 2000), with PS antioxidant effects being increasingly related to their high ability to act as free radicals scavenger and stabilizer of cell membranes and even act as a boost for antioxidant enzymes (Van Rensburg et al., 2000; Nashed et al., 2005; Brüll and Mensink, 2009). In addition, the inflammatory process is increasingly related to oxidative stress and reactive oxygen species (ROS) overproduction, so bioactive molecules with pronounced antioxidant effects also have interesting anti-inflammatory potential, and PSs are not an exception. A study performed by López-García and coworkers (López-García et al., 2020) found that a PS-enriched milk-based fruit beverage with/without galactooligosaccharides blocked...
TABLE 1 | Preclinical phytosterol (PS) bioactive effects and the respective mechanisms of action.

| Bioactive effects          | Mechanism of action                                                                 | Reference                                                                 |
|----------------------------|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Anticancer                 | Decrease the number of aberrant crypt and crypt multiplicity. Attenuate β-catenin and PCNA expression. Trigger apoptosis, through increasing Fas protein expression, caspase 8, TRAIL, BAD diphosphorylation, mitochondrial depolarization and caspase 3-dependent PARP cleavage, intracellular Ca2+ influx, rise in ROS levels, cell cycle arrest at phase G0/G1 and S and cell necrosis. Decrease mammary hyperplastic lesions and total tumor burden. Cell cycle arrest at G2/M phase. Interferes in DNA fragmentation. | Daniel et al. (2001); Awad et al. (2007); Baskar et al. (2010); Herbst et al. (2010); Cilla et al. (2015); López-García et al. (2017); Alvarez-Sala et al. (2018a) |
| Antioxidant                | Free radical scavenger. Cell membranes stabilizer. Antioxidant enzyme booster.       | Van Rensburg et al. (2000)                                                |
| Anti-inflammatory          | Macrophage- and neutrophil-mediated inflammatory process. Evoke Th1 cell response. Decrease edema. Decrease proinflammatory cytokine levels. Interferes in matrix degradation mediators. Increase the remission periods in GI tract diseases, improving colon shortening and blocking mucosal colonic damage. | Nashed et al. (2006); Brüll and Mensink (2009); López-García et al. (2019); López-García et al. (2020) |
| Antidiabetic               | Glucose metabolism modulation. Interferes with AMPK and peroxisome proliferator-activated receptors. | Zaklos-Szyda (2015)                                                       |
| Antiatherosclerotic/effects on lipid profile | Cholesterol absorption blockade. Decrease LDL-C and VLDL secretion and accumulation. Decrease plasma and hepatic TG levels. | Moghadasi (2000)                                                          |
| Neuroactive effects        | Reduce Aβ plaque formation, counteract memory deficits, increase the acetylcholine levels in brain, and increase Aβ clearance. | Schepers et al. (2020)                                                    |
| Antierthyptotic and anthemolistic effects | Prevent eryptosis; reduce Ca2+ influx, ROS overproduction, GSH depletion, and hemolysis. | Alvarez-Sala et al. (2018d)                                               |
| Microbiota modulation effects | Promoters of beneficial species abundance, affecting the Erysipelotrichaceae and Eubacterium family proportions. | Cuevas-Tena et al. (2018)                                                 |

AMPK, adenosine monophosphate (AMP)-activated kinase; DNA, deoxyribonucleic acid; GI, gastrointestinal; LDL-c, low-density lipoprotein cholesterol; PCNA, proliferating cell nuclear antigen; PSs, phytosterols; TG, triglycerides; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; VLDL-C, very-low-density lipoprotein cholesterol.

In vivo studies proved that stigmasterol could inhibit various proinflammatory and matrix degradation mediators involved in triggering osteoarthritis-induced cartilage degrading, at least in part through nuclear factor kappa B (NF-kB) pathway inhibition (Gabay et al., 2010).

Antidiabetic Effects

Some studies have identified PSs as key modulators of glucose metabolism, through acting on AMP-activated kinase (AMPK) activation or peroxisome proliferator-activated receptors (PPARs) to transcriptional regulation pathways (Zaklos-Szyda, 2015). Hwang et al. have indicated that β-sitosterol (20 μM) handling of L6 muscle cells increases glucose intake across increased GLUT4 translocation to the plasma membrane (Hwang et al., 2008). A limited rise in blood glucose scale after oral administration of high glucose concentration and increased insulin response was observed in Zucker diabetic fatty rats supplemented with 5-campestanone (0.6%) (Konno et al., 2005). A prominent decrease in blood glucose levels with concurrent glucose elimination inhibition in urine was reported in db/db mice fed with 0.3% 5-campestanone after eight weeks (Suzuki et al., 2002).
Effects on Lipoprotein Metabolism

In accordance with various surveys, PS administration led to a reduction in total cholesterol (TC) and LDL-C levels by blocking dietary cholesterol absorption and further impacting its hepatic/intestinal biotransformation (Moghadasian, 2000). Male C57BL/6 J mice with high-fat diet supplementation together with 3.1% PS administration for three weeks presented a decrease in very-low-density lipoprotein (VLDL) secretion, while no distinction was found in chylomicron secretion (Schonewille et al., 2014).

Epidemiological and experimental data have affirmed that a high-cholesterol diet is detrimental to cognitive performance in animal models. Rui et al. proved that rats fed with a high-cholesterol diet supplemented with 2% g/100 g PS for 6 months maintained body mass match, reduced serum lipid levels, improved cognitive performance, triggered an increase in pyramidal cells number, and had an obvious reduction in the number of astrocytes (Rui et al., 2017).

Several studies have emphasized the role of PSs in plasma and hepatic triglycerides (TG) levels modulation (Rideout et al., 2015b). Rideout et al. assessed the effect of diet supplemented with 2% w/w PSs on Syrian golden hamsters fed with a high-fat diet for 6 weeks (Rideout et al., 2014). Curiously, the decrease in blood TG in the PS group was similar to that using ezetimibe (Rideout et al., 2014). Similar results were found in other animal studies, considering that some factors, such as the type of diet applied, PS dosage, test period, and diurnal regulation of lipid levels, could contribute to the differences observed in TG-lowering level and associated mechanisms (Pan et al., 2010; Schonewille et al., 2014). Thus, given the main findings from animal experiments, it was proposed that PSs are able to lower circulating TG levels through mechanisms involving the reduction of TG and FA uptake, a rise in fecal FA excretion, a decrease in duodenal bile acid excretion, and modulation of hepatic FA and TG metabolism (Rideout et al., 2015a). Some in vivo studies with different animal models have delivered conflicting results, such as the case of Brufau et al., who investigated the effect of 2.45% g/100 g PS supplementation on guinea pigs with a high-saturated fat diet for 4 weeks (Brufau et al., 2007). The authors did not state changes in medium chain FAs excretion, but medium/short-chain FA excretion decreased, while an increase in long-chain FA excretions was detected (Brufau et al., 2007). In addition, although total saturated FA fecal excretions did not change, the shift toward greater excretion of longer chain and more hydrophobic saturated FA suggest a reduction in intestinal lipid solubilizing potential, and the study period selected for this experiment may have also affected the obtained results.

Antiatherosclerotic Effects

Antiatherosclerotic properties of plant sterols are properly developed in several animal models and directly associated with their cholesterol-lowering effects (Jessup et al., 2008). Shariq et al. (2015) studied the antiatherosclerotic effect of virgin coconut oil reported to contain increased levels of PSs on male Wistar rats. The findings revealed a considerable decrease in body weight, TC, TG, LDL, and VLDL and a significant increase in high-density lipoprotein (HDL) levels correlated with antiatherosclerotic effects. Various investigations have also explained a modulatory role for PSs on atherosclerosis due to their anti-inflammatory effects (Nashed et al., 2005; Calpe-Berdiel et al., 2007). PSs were found to reduce proinflammatory cytokine generation, namely, IL-6 and tumor necrosis factor (TNF)-α, and increase the Th1/Th2 ratio and the level of Treg cytokine IL-10 in splenocytes of ApoE−/− mice (Nashed et al., 2005; Calpe-Berdiel et al., 2007).

Increased serum IL-10 levels have also been correlated with a severe reduction in atherosclerotic lesion size (Pinderski et al., 2002; Nashed et al., 2005). A marked reduction in atherosclerotic lesions size was also linked to a prominent reduction in other constituents, such as the number of foam cells and cholesterol clefts, extracellular matrix amounts, and the extent of apparently proliferative smooth muscle cells (Moghadasian, 2000). ApoE-deficient mice fed on a diet supplementation with 2% PS for 14 weeks led to changes in the expression of 132 genes, with particular emphasis on hepatic genes involved in sterol biotransformation regulation (Xu et al., 2008). All these changes allow a better understanding of how PSs mechanistically exert their cardioprotective action.

Other Effects

Besides the above listed biological activities of PSs, some recently published studies have also underlined interesting effects, namely, to what concerns to its antierptotic and antihemolytic effects and neuroprotective and even microbiota modulatory abilities. In an in vitro study, Alvarez-Sala and colleagues used a selected PS mixture, composed of β-sitosterol, campesterol, stigmasterol, or β-cryptoxanthin (β-Cx), and observed that the use of β-Cx led to an increase in apoptotic cell number and volume, hemolysis, and glutathione depletion (GH) without ROS overproduction and intracellular Ca2+ influx (Alvarez-Sala et al., 2018d). On the other side, PSs prevented eryptosis, reduced Ca2+ influx, ROS overproduction, GH depletion, and hemolysis. However, when both bioactive compounds were coincubated, they completely prevented hemolysis, prevented eryptosis and GH depletion, and thus may be considered promissory candidates for eryptosis-associated disease healing.

In another study, Cuevas-Tena et al. (2018) assessed the plant sterol influence on gut microbiota and vice versa. As main findings, the authors stated that both Erysipelotrichaceae and Eubacterium family proportions were affected by high-dose plant sterols, at the same time that sitosterol and stigmasterol decreased while its metabolites increased. Concomitantly, low TC conversion was stated under plant sterols presence. Thus, plant sterols may be viewed as promoters of beneficial species abundance (Cuevas-Tena et al., 2018).

More recently, Schepers et al. (2020) highlighted in a review article prominent neuroactive effects of PSs derived from marine origin. As main statements, the authors clearly highlighted the ability of fucosterol, 24(S)-saringosterol, sitosterol, and stigmasterol to reduce Aβ plaque formation; the ability of fucosterol and 24(S)-saringosterol to counteracts memory deficits; the ability of fucosterol to increase the acetylcholine levels in the brain; and the ability of 24(S)-saringosterol to increase Aβ clearance (Schepers et al., 2020).
Adverse Effects

Specifically addressing the possible adverse effects related to PSs, first, it is worth noting that in vitro studies have shown that high β-sitosterol amounts can trigger human umbilical vein endothelial cells shrinking (Rubis et al., 2008). Second, particularly addressing in vivo studies, it should be highlighted that some animal species, such as rodents, may not represent a proper prototype due to the remarkable variations between them and humans in sterol metabolic process (Dietschy and Turley, 2002), although several animal studies have indicated possible undesirable adverse effects of PSs. For example, Chen et al. reported that WKY inbred rats consuming diets containing PSs or phytostanol had a notable rise in systolic and diastolic blood pressure correlated with increased renal angiotensinogen mRNA levels (Chen et al., 2010). Wild-type mice fed with PS or phytostanol diets also showed impaired endothelium-dependent vasorelaxation and grown cerebral lesion area after middle cerebral artery occlusion (Weingartner et al., 2008). In addition, high PS concentrations in plasma of both male and female laboratory animals may have adverse effects on their generative organs (Malini and Vanithakumari, 1990). In rats, both testosterone and estradiol levels in males and females, respectively, were also raised due to β-sitosterol intake (Ryokkynen et al., 2005).

On the other hand, it is also convenient to highlight that plants often accommodate traceable amounts of oxidized derivatives of PSs (oxyPS). These compounds are noticeable in atheromatous plaque, and this may demonstrate their engagement in atherosclerosis expansion (Patel and Thompson, 2006). However, the number of investigations conducted so far is not acceptable to assess the exact metabolic action of oxyPS. In such a way, a recent study published by Alvarez-Sala and colleagues (Alvarez-Sala et al., 2018b) measured both the level of oxidized sterols formed and its bioaccessibility in a plant sterol-enriched milk-based fruit beverage with milk fat globule membrane at 0-, 3-, and 6-month storage. As main findings, the authors did not state considerable changes during storage, meaning that such formulation was maintained stable over the studied period, without an increase in oxidized sterols’ contents and bioaccessibility, and thus may be considered as a suitable PS-enriched food matrix for extended shelf-life, in addition of being safe for consumers (Alvarez-Sala et al., 2018b). Nonetheless, the authors just assessed a single preparation, and thus further studies are still needed in such a way.

PHYTOSTEROLS IN CLINICAL TRIALS

Phytosterols and Cardiovascular Risk

A plethora of studies have explored distinct aspects of the clinical efficacy of plant sterols/stanols in lowering LDL-C levels. There have been more than five decades of research on PSs to prove its efficacy in decreasing cholesterol levels. It was shown that PSs inhibit cholesterol intake via cholesterol displacement from micelles (Ling and Jones, 1995), thus reducing the risk of CV diseases (Vahouny et al., 1983; Ikeda et al., 1988) (Figure 3).

A survey of 46 patients (Lees et al., 1977) with type II hyperlipoproteinemia was conducted to evaluate the effect of plant sterols preparations from two distinct sources and in two physical forms in lowering plasma TC levels, administered along with appropriate diet therapy. The PS hypocholesterolemic potential was also assessed in seven patients by a sterol balance technique, revealing inhibition of TC intake. The maximal mean TC lowering was 12%, which suggests the PS potential value as a dietary therapy adjunct in mild hypercholesterolemic patients (Lees et al., 1977).

A clinical trial performed in 153 mild hypercholesterolemic patients revealed that substituting sitostanol-ester margarine as part of the normal daily dietary fat is effective in lowering serum TC and LDL-C, thus having favorable effects (Miettinen et al., 1995). Another report summarizing information from a meta-analysis of 41 trials on sterols and stanols efficacy and safety profile demonstrated that consumption of 2 g/d of stanols or sterols decreased LDL-C by 10% (Katan et al., 2003). Epidemiological studies with TC-lowering drugs showed that its long-term use in the first five years reduces the CV disease risk by 12%–20%, whereas...
lifetime use reduces it by 20%. Additionally, the adverse effects of plant sterols intake into blood circulation were found to be hypothetical in adults. This study agrees with another meta-analysis of 59 clinical trials (Abumweis et al., 2008), where plant sterols (and stanols)-containing product use when compared to placebo was linked to a reduction in LDL-C levels. An investigation performed to evaluate the PS role in changing plasma lipid levels, when incorporated into nonfat or low-fat beverages on moderately hypercholesterolemic men and women (Jones et al., 2003), revealed that PS absorption in the low-fat beverage format is not effective in changing the lipid levels, namely, HDL-C and triacylglycerol (TAG).

While earlier no significant changes in TG levels were documented with the use of stanols and sterols, some meta-analyses have reported a small, but statistically significant decrease in TAG levels (Gupta et al., 2011). Moreover, it has been found that the daily use of 1.6–3 g of esterified PS in the first month of therapy reduces LDL-C levels by 4.1–15% when compared to placebo (O’Neill et al., 2005).

In a clinical study assessing the effects of plant stanol and sterol esters on serum PS levels in individuals with familial hypercholesterolemia, a reduction in serum TC levels was documented, although the clinical role of increased plant sterol contents was not known (Ketomaki et al., 2004). In a nine-week trial with metabolic syndrome patients receiving a daily dose of 2 g stanol esters, a remarkable decline in non-HDL-C and TAG levels was documented (Plat et al., 2009). Moreover, the TAG effects were also present in combination with a low dose (10 mg) simvastatin treatment, thus depicting the additional benefit of stanol esters use in individuals with CV disease risk.

In another study, the effects of the absorption of three phytosterols on whole-body TC metabolic pathway were determined in 18 adults receiving a phytosterol-deficient diet (50 mg PS/2000 kcal) plus beverages supplemented with 0, 400, or 2000 mg PS/day for four weeks each in a random order (Racette et al., 2010). Dietary PS, at moderate (459 mg/day) and high (2059 mg/day) dosages, dose-dependently improved biliary and dietary TC excretion and decreased the efficiency of intestinal TC absorption. In another study, this group of researchers also reported a significant reduction in intestinal TC absorption and an increased fecal TC excretion during ezetimibe administration plus plant sterols (2 g/day) when compared to ezetimibe alone (Lin et al., 2011). This data indicates that PS combination with ezetimibe not only improved the ezetimibe effects, thus emphasizing the dietary importance of PS as additive therapy for hypercholesterolemia. In addition, it has been reported that the effective daily dose range of PS is between 1 g and 3 g, beyond which it offers no additional benefits and fully effective therapy can take up to eight weeks (Malinowski and Gehret, 2010).

Another clinical study with 41 men and women designed to explore the activity of PS capsules on circulating LDL-C levels in patients with mild-to-moderate hypercholesterolemia revealed that daily PS intake in capsules (2 g) did not decline TC or LDL-C levels (Ottestad et al., 2013). These findings emphasize the need for choosing a suitable dose delivery system to reach optimal TC-lowering effects.

A clinical trial with 182 hypercholesterolemic adults was performed to assess the long-term effectiveness of 2 g/day of plant stanols for 12 months in reducing LDL-C levels (Parraga-Martinez et al., 2015). As main findings, >10% reduction in plasma LDL-C levels was stated from baseline at both three months and one year of consumption, hinting its role in reducing CV disease risk.

As plant sterols have been reported to reduce plasma LDL-C, a double-blind randomized placebo-controlled parallel-group study was performed in hypercholesterolemic patients (Ras et al., 2013). Healthy men and women used low-fat spreads without or with added PS (3 g/d) for 12 weeks after a four-week run-in period (Ras et al., 2013). The time curves of changes in plasma PS for 12 weeks of PS intake and the impact of TC synthesis and absorption in plasma PS were also exploited. The authors stated a plasma PS levels stabilization within four weeks of PS intervention, which were not impacted by basal TC synthesis or absorption efficiency.

Due to the high prevalence of lactose intolerance in China, a study was designed to evaluate if PS-rich milk is effective in lowering serum LDL-C (Cheung et al., 2017). Other participants (n = 221) without TC-lowering drugs or diabetes mellitus were assigned to a daily intake of PS-rich low-fat milk, containing 1.5 g PS/day or conventional low-fat milk for three weeks. Blood profile and physical examination were also performed. As compared to control, the treated group depicted a remarkable decline in serum LDL-C and TC levels and diastolic blood pressure; thus, it can be used as part of a healthy diet.

A three-arm, double-blind, randomized clinical trial in mildly hypercholesterolemic subjects was conducted to analyze the effects of PSs, red yeast rice, or both nutraceuticals on lipid parameters with good short-term tolerability (Cicero et al., 2017). It was documented that the additive lipid-lowering effect of PSs and red yeast rice enhanced lipid parameters with good short-term tolerability as depicted by a significant reduction in LDL-C and apolipoprotein B levels comparing with individual treatments of these two nutraceuticals. In addition, a double-blind randomized placebo-controlled crossover intervention study was performed with healthy volunteers (without or mild hypercholesteremia) to assess the activity of plant sterol esters supplemented margarine on TC, non-TC sterols, and oxidative stress in serum and monocytes (Weingartner et al., 2017). The authors stated that plant sterol ester consumption supplemented margarine led to a rise in plant sterol contents and TC synthesis markers, without affecting serum TC and activating circulating monocytes or redox state (Weingartner et al., 2017).

Considering the high occurrence of nonalcoholic fatty liver, the role of dietary cholesterol in liver inflammation, and the PS action on TC metabolism, the PS therapeutic potential against nonalcoholic fatty liver disease has also been explored (Javanmardi et al., 2018). It has been documented that, as compared to the placebo, PS additive remarkably enhanced LDL-C, aspartate aminotransferase, alanine aminotransferase, and TNF-α levels. However, no remarkable differences were stated between the two groups with regard to TC, TG, HDL-C, VLDL-C, LDL-C/HDL-C, and TC/HDL-C.
ratios, gamma-glutamyl transferase, IL-6, high-sensitivity C-reactive protein (hs-CRP), adiponectin, and leptin levels.

The effect of dietary intervention with PSs, with or without curcumin, on blood lipids in hypercholesterolemic individuals was also investigated in a double-blind, randomized, placebo-controlled, 2 × 2 factorial trial (Ferguson et al., 2018). The authors documented that curcumin addition to PS therapy led to a complementary TC-lowering effect, larger than PS therapy alone without adverse effects. Another study assessed the TC-lowering activity of 2 g of plant sterols from sterol-rich cereals through the form of a whole grain wheat biscuit, in 50 volunteers with a TC > 5.5 mmol/L in a randomized crossover trial with two four-week periods (Clifton and Keogh, 2018). It was observed that the LDL-C lowering effect of the whole grain wheat biscuit did not vary from other foodstuff delivering 2–2.5 g of plant sterols daily. Recently, a study assessed the gender differences in LDL-C lowering activity post-PS intervention (San Mauro-Martín et al., 2018), where milk intake with 2.2 g/day of added PSs significantly lowered LDL-C levels in men. In studies on prepubertal children with familial hypercholesterolemia, dietary plant sterol/stanol consumption did not ameliorate endothelial function despite the significant decrease in LDL-C levels (De Jongh et al., 2003; Jakulj et al., 2006). Interestingly, some early reports have documented that the mildly elevated plant sterol levels are positively impacted with vascular disease (Sudhip et al., 2002; Assmann et al., 2006), whereas others referred to an inverse or even lack of association between circulating plant sterols and CV disease risk (Windler et al., 2009; Escurriol et al., 2010). Such variations in PS effects have been increasing exploited in a tentative way of clarifying the different findings obtained by different authors (Borel and Desmarchelier, 2018). Some recent studies have found variations in both PS absorption and consequent bioavailability, attributed to genetic polymorphisms, namely, that of ABCG5/G8, as other proteins/genes directly or indirectly involved in PS transportation to enterocyte, blood, and even other tissues. Moreover, variations in both Niemann-Pick C1 Like 1 transporter (NPC1L1) and apolipoprotein E (APOE) have also been reported as having a great impact on PS bioavailability (Borel and Desmarchelier, 2018). More detailed attention is given in the section PS bioavailability.

Phytosterols and Cancer Risk

Dietary and lifestyle factors play a critical role in cancer etiology. PSs are well recognized for their role in maintaining blood TC levels, but their potential in the area of anticancer research is still unexplored, with case-control studies showing no causal effect (Figure 4). For example, a randomized, double-blind, placebo-controlled multicenter trial in patients with benign prostatic hyperplasia (BPH) was performed over 6 months, using β-sitosterol (which contains a mixture of PSs) three times/day or placebo (Berges et al., 1995). Although no relevant decline in prostatic volume was observed in the β-sitosterol and placebo group, a remarkable improvement was seen in symptoms and urinary flow parameters, revealing the β-sitosterol effectiveness. Similar results were reported in another clinical study, using the β-sitosterol for the treatment of BPH, where results demonstrated slightly more rapid changes than that stated by Berges et al., (1995) with a difference of 2.6 points over placebo after four weeks (Klippel et al., 1997). A case-control study was also performed to determine the protective role of plant sterols in lung carcinogenesis in 463 subjects (Mendilaharsu et al., 1998). It was concluded that the highest quartile intake of PSs led to a 50% reduction in lung cancer risk. Another case-control study found that the highest PS intake is inversely related to gastric cancer risk (De Stefani et al., 2000).

Looking at ovarian cancer, a case-control study was conducted in 124 confirmed ovarian cancer cases to determine the impact of food diet, via a detailed food frequency questionnaire (Mccann et al., 2003). As compared with women in the lowest quintile of intake, a lower risk was documented for women in the highest quintile of stigmastanol intake, thus supporting the assumption that phytoestrogen intake exerts a protective action on ovarian cancer (Mccann et al., 2003). Conversely, in a cohort study on 3,123 subjects with colon and rectal cancer risks, no association was observed between PS intake and a lower risk of colon and rectal cancers (Normen et al., 2001). Moreover, a recently published meta-analysis aiming to provide a comprehensive synopsis on PS intake and cancer risk highlighted a linear association for campesterol and a nonlinear association for total PS intake and cancer risk. Such findings support that high PS intake is inversely related to cancer risk, although further and more in-depth studies are needed, particularly of prospective design to more clearly know the PS contribution to anticancer effects (Jiang et al., 2019).

Phytosterols and Gestational Diabetes

Gestational diabetes mellitus (GDM) is a rapidly growing serious health complication over pregnancy. A clinical study designed to assess the action of a PS-rich margarine spread daily consumed on insulin resistance and lipid profile in GDM women revealed that, after 16 weeks, TAG, TC, and LDL-C levels were remarkably reduced, while HDL-C increased when compared to baseline (Li and Xing, 2016). Additionally, fasting plasma glucose and serum insulin levels, insulin check index, and β-cell function were also remarkably improved. In another clinical study, the effect of PS-rich margarine spreads consumed daily was assessed on both maternal and neonatal outcomes of GDM patients (Gao et al., 2017). It was observed that the daily consumption of the PS-rich spread led to remarkable benefits on maternal diabetic symptoms, namely, in improving lipid composition and glucose metabolism and decreasing the incidence of neonatal complications.
In vitro and ex vivo investigations have demonstrated that plant sterols and stanols can shift the T helper (Th) 1/Th2 balance toward a Th1-type immune response, which may be beneficial in Th2-dominant conditions, such as asthma and allergies. In another study, the effects of plant stanol esters on the immune response of asthma patients were assessed (Brüll et al., 2016). For that, 58 asthmatic patients were recruited, with half of them receiving plant stanol-rich soy-based yogurts (4.0 g plant stanols/day), while the others consumed control yogurts (Brüll et al., 2016). It was found that asthmatic patients receiving plant stanol-rich soy-based yogurts had higher antibody titers against hepatitis A virus (3 and 4 weeks after vaccination) and marked reductions in plasma total Ig-E, IL-1β, and TNF-α levels (Brüll et al., 2016); thus, plant stanol ester consumption was able to improve the immune function in asthmatic patients. More recently, Alvarez-Sala et al. (2018a) assessed the impact of a milk-based fruit beverage with a milk fat globule membrane on the levels of cholesterol and cholesterol precursors, serum biomarkers, and cytokines in postmenopausal women. As main findings, the authors stated a marked decrease in TC and LDL levels and a marked increase in the precursor lanosterol with a concomitant decrease in the proinflammatory cytokine IL-1β; such observations clearly underline that this beverage may promote the CV health in postmenopausal women given its impact on both inflammatory status and CV risk factors (Alvarez-Sala et al., 2018c).

Phytosterols and Osteoporosis

A clinical trial analyzed the effect of β-Cx plus PSs on CV risk and bone turnover markers in postmenopausal women, who are at higher risk of CV disease and bone demineralization (Granado-Lorencio et al., 2014). Interestingly, it was observed that β-Cx enhances the TC-lowering action of PSs when simultaneously supplied with this combination providing benefits in reducing the risk of osteoporosis.

The clinical trials of PSs performed on CV risk, cancer risk, gestational diabetes, immunomodulation, and osteoporosis are summarized in Table 2.
**BIOAVAILABILITY OF PHYTOSTEROLS**

PSs are absorbed from food in the proximal small bowel and incorporated into micelles (Salen et al., 2006; Miras-Moreno et al., 2016). At the same time, the PS absorption is lesser than that of cholesterol, because of intestinal lumen selectivity and return, through an ABC-transporter–mediated process. Only a small amount of PSs administered with food is absorbed and reaches the systemic circulation (Ostlund et al., 2002). In addition, PSs are not produced in the human organism, and the concentration of PSs circulating in the human body is two hundred times less than that of cholesterol in subjects with the usual type of nutrition (Chan et al., 2006; Ras et al., 2013).

According to Miettinen et al. (1990), the content of plant sterols in human blood is only 0.1–0.14% of TC level. In a healthy human, sitosterol/cholesterol ratio on a molar basis is around 1 to 800–1,000 (Shahzad et al., 2017). Mellies et al. (1976) found that 300–900 mg/day of plant sterol consumption with food led to a significant amassing in plasma (0.44 μM) of children (Mellies et al., 1976).

In some studies, it appeared that plant sterol conversion to stanols significantly reduces LDL-C serum levels (Ikeda and Sugano, 1978; Sugano et al., 1978; Becker et al., 1993). Since nonesterified stanols may have restricted bioavailability to block cholesterol intake (Denke, 1995), a trial was made to increase their bioavailability by converting nonesterified bioavailable stanols into FA stanol esters (Heinemann et al., 1986). Plant stanols esters can easily dissolve in oils or margarine. They suffer intestinal hydrolysis, releasing nonesterified stanols bioavailable to block cholesterol absorption in the intestine.

**In Vitro Phytosterol Bioavailability**

Baldi and Pinotti reported that milk fat is an effective delivery system for highly hydrophobic compounds, such as PSs (Baldi and Pinotti, 2008). In addition, the occurrence of lecithin or unsaturated FA (oleic, linoleic, and α-linolenic acids) (Brown et al., 2010) may improve cholesterol and/or PS inclusion in a micelle-mixed bile model.

Some studies have also focused on sterols solubility assessment after digestion product imitation containing orange juice enriched with PS or multivitamin/mineral tablets dissolved in orange juice (Bohn et al., 2007), PS-rich commercially available fermented milk beverages (Vaghini et al., 2016), and skimmed milk and/or fruit beverages. Data show that both matrix and component mixture of PSs present in food have a key effect on their bioavailability. For example, Alvarez-Sala et al. developed a functional milk-based fruit drink with PSs modified with lipid components/emulsifiers to increase PS bioavailability. The authors found that the content of the sum and individual PSs, fat, type of emulsifier, and homogeneity in beverages differed (Alvarez-Sala et al., 2016). Individual PSs in one and the same beverage showed a similar bioavailability, except the beverage without fat addition, where the highest bioavailability corresponded to campestanol. In the beverage, with olive oil and soy lecithin inclusion (where there was less homogeneity), stigmasterol had the lowest bioavailability. Beverages with higher fat content (2.4%) revealed higher PS bioavailability (31.4% and 28.2%, respectively) compared to those where the fat content was 1.1% (8.7%). According to the authors, the fat content in the food matrix may contribute to mixed micelles formation during gastrointestinal (GI) digestion. In general, data showed that PS bioavailability is influenced by both fat type/amount and the type of emulsifier used (Alvarez-Sala et al., 2016). In addition, milk fat and whey proteins addition increase the bioavailability of both the sum and individual PSs, in particular, campestanol, and stigmastanol (Alvarez-Sala et al., 2016).

Nik et al. found in a simulated digestion model in the duodenum that β-sitosterol, campesterol, and stigmastanol bioavailability (transfer to the aqueous micellar phase) ranged from 72 to 93% (Nik et al., 2011). These data were higher than that reported in another study (Alvarez-Sala et al., 2016), possibly due to a less complex food matrix.

Vaghini et al. and colleagues investigated the bioavailability of both selected plant sterols and stanols from four (A–D) commercial fermented milk drinks using in vitro GI digestion, including mixed micelles formation. PS amount in beverage samples ranged from 1.5% to 2.9% (w/w). β-sitosterol was present in all samples but prevailed in samples A and B (about 80% of the total PS number) (Vaghini et al., 2016). Campesterol concentration in the samples was as follows: C (22%) > A (7%) > B (5%). Sitosterol was the most common in sample D (85%), while stigmasterol was only present in sample C (33%). The highest degree of bioavailability in the PS sum was related to samples A and B (16–17%), followed by D (11%) and C (9%). The PS sum bioavailability was not related to protein, lipids, or PS content in beverages, while in samples with higher carbohydrates and fiber content, bioavailability was lower. The individual PS bioavailability differed relatively to the sample and was not related to sample’s PS profile, indicating a high dependence on food matrix composition.

Studies searching for mutations that cause sitosterolemia were original research aiming to identify genetic variations associated with PS bioavailability. Findings from these studies allowed us to associate this disorder with mutations in ABCG5 and ABCG8 genes, encoding 2 ATP-binding cassettes (sterolin-1 and -2) associated this disorder with mutations in ABCG5 and ABCG8 genes, encoding 2 ATP-binding cassettes (sterolin-1 and -2) genes, encoding 2 ATP-binding cassettes (sterolin-1 and -2) acting as hemitransporters (Borel and Desmarchelier, 2018). These proteins are responsible for PS removal from enterocytes into enteral lumen and hepatocytes from bile. This finding indicates that genetic polymorphisms in these genes may modulate PS bioavailability, although probably less; therefore, it is asymptomatic. This has been confirmed by several associative studies (Borel and Desmarchelier, 2018). However, these results do not present definitive evidence that single nucleotide polymorphisms in these transporters affect the intestinal PS absorption. It seems feasible that the observed associations may be due to the PS effects on hepatocyte excretion but not on enterocytes. Other authors also showed that single nucleotide polymorphisms in ABCG8 can modulate changes in PS content in the blood, thus affecting their bioavailability (Borel and Desmarchelier, 2018).

PS bioavailability is not only controlled by ABCG5/G8, as other proteins/genes directly or indirectly participate in PS transportation through the enterocyte, as well as into the
| Disease/reference | Type of study and subjects | Treatment | Outcomes |
|------------------|---------------------------|-----------|----------|
| Cardiovascular risk | CT type II hyperlipoproteinemic patients (n = 46). Duration: 7 years | Plant sterols preparations from two distinct sources and in 2 physical forms (soy sterols suspension (18 g/day) and powder (18 g/day) and tail oil sterols suspension (3 and 6 g/day) and powder (3 g/day)) | Decrease in plasma TC (12%, p = 0.001) and LDL-C (17%, p < 0.001) levels |
| Lees et al. | RCT mild hypercholesterolemic patients (n = 153). Duration: one year | Sitostanol-ester margarine (n = 102; 1.8 and 2.6 g/day) and margarine without sitostanol (n = 51) | 10.2% and 14.1% decrease in serum TC and LDL-C levels in the sitostanol group and 0.1% and 1.1% in the control group, respectively (p < 0.001) |
| Miettinen et al. | CT moderately hypercholesterolemic patients (men and women; n = 15). Duration: 21 days | Nonfat placebo and nonfat and low-fat beverages with added PS | PS absorption in the low-fat and nonfat beverages was not effective in changing HDL-C and triglyceride levels |
| Jones et al. | CT family with familial hypercholesterolemia. Duration: 3-4 weeks | Plant stanol and sterol esters on serum PS levels | Reduction in serum TC (14%) and LDL-c (17%) levels (p < 0.001) |
| Ketomaki et al. | RCT mild hypercholesterolemic subjects (n = 21). Duration: 3 weeks | PS-controlled diet plus (1) ezetimibe placebo + PS placebo, (2) 10 mg ezetimibe/day + PS placebo, and (3) 10 mg ezetimibe/day + 2.5 g PS/day | Reduction in intestinal TC absorption (p < 0.0001) and an increased fecal TC excretion (p < 0.0001) during ezetimibe administration plus PS, when compared to ezetimibe alone |
| Pfitz et al. | RCT metabolic syndrome patients (n = 36). Duration: 9 weeks | Placebo (n = 9), simvastatin + placebo drink (n = 10), placebo + stanol drink (n = 9), and simvastatin + stanol drink (n = 8) | Moderate (459 mg/day) and high (2059 mg/day) dosages, dose-dependently improved biliary and dietary TC excretion (p < 0.01), and decreased intestinal TC absorption efficiency (p < 0.01) |
| Racette et al. | CT adults receiving a PS-deficient diet (50 mg PS/200 kcal), supplemented with different PS doses (n = 18). Duration: 4 weeks | Three PS doses (59, 459, 2059 mg PS/day) | Daily PS intake in capsules did not decline TC (p = 0.74) or LDL-C (p = 0.32) levels |
| Lin et al. | RCT mild hypercholesterolemic adults (n = 182). Duration: 12 months | Plant stanol (2 g/day) group and control group (receiving unsupplemented yogurt) | >10% reduction in plasma LDL-C levels was stated (p = 0.011) from baseline at both three months and one year of plant stanol consumption |
| Cheung et al. | RCT adults (n = 221) without TC-lowering drugs or diabetes mellitus (41 men and 180 women). Duration: 3 weeks | PS-rich low-fat milk, containing 1.5 g PS/day (n = 111) or a conventional low-fat milk (n = 111) | Additive lipid-lowering effect of PS and red yeast rice enhanced lipid parameters with a marked reduction in LDL-C (−20.5%, p < 0.001) and apolipoprotein B (−14.4%, p < 0.001) levels compared with individual treatments of these two nutraceuticals |
| Cicero et al. | RCT mild-to-moderate hypercholesterolemic subjects (n = 90). Duration: 8 weeks | PS (800 mg), red yeast rice (5 mg monacolins), or both combined nutraceuticals | Plant sterols led to a rise in serum levels of plant sterols (campesterol, p = 0.005; sitosterol, p < 0.001) and of TC synthesis (desmosterol, p = 0.006; lanosterol, p = 0.012) markers, without affecting serum TC and activating circulating monocytes or redox state |
| Weingartner et al. | RCT healthy volunteers, with no or mild hypercholesterolemia (n = 16). Duration: 4 weeks | Plant sterols (3 g/day) via a supplemented margarine | Compared to placebo, PS group remarkably enhanced LDL-C (p = 0.030), AST (p = 0.010), ALT (p < 0.001), and TNF-a (p = 0.006) levels. No differences were stated between the two groups with regard to TC, TG, HDL-C, VLDL-C, LDL-C/HDL-C, and TC/HDL-C ratios, gamma-glutamyl transferase, IL-6, hs-CRP, adiponectin, and leptin levels |
| Javanmardi et al. | RCT nonalcoholic fatty liver disease patients (n = 38). Duration: 8 weeks | PS group (n = 19, received 1.6 g PS supplement) and control group (n = 19, 1.6 g starch daily) | Curcumin addition to PS led to a complementary TC-lowering effect, larger than PS therapy alone (p < 0.0001), with no adverse effects |
| Ferguson et al. | RCT hypercholesterolemic individuals (n = 70). Duration: four weeks | Placebo (n = 18, no PS or curcumin), PS (n = 17, 2 g/day), curcumin (n = 18, 200 mg/day), and PS + curcumin (2 g/day + 200 mg/day) | (Continued on following page) |
### TABLE 2 | (Continued) Clinical studies with PS effects in humans.

| Disease/reference | Type of study and subjects | Treatment | Outcomes |
|-------------------|---------------------------|-----------|----------|
| **Clifton et al.** | RCT volunteers with a TC > 5.5 mmol/L (n = 50). Duration: 2 × 4 weeks | Breakfast wheat biscuit (2 g PS) and standard whole grain wheat breakfast cereal biscuit | LDL-C lowering effect between wholegrain wheat biscuits and plant sterol-enriched wholegrain wheat breakfast cereal biscuit was 0.23 mmol/L (5.6%, p = 0.001) |
| **San Mauro-Marín et al.** | RCT gender differences in LDL-C lowering activity of PS (n = 30 women and 24 men). Duration: 2 × 3 weeks | 2.2 g/day of added PS in 700 ml milk | PS-enriched milk intake led to a decrease in LDL-C levels in men |
| **Cancer** | Berges et al. RCT patients with benign prostatic hyperplasia (n = 200). Duration: 6 months | B-sitosterol (20 mg, which contains a mixture of PS), three times/day or placebo | Remarkable improvement (p < 0.01) in symptoms score and urinary flow parameters, thus revealing the β-sitosterol effectiveness |
| | Klippel et al. RCT patients with benign prostatic hyperplasia (n = 177). Duration: 6 months | β-sitosterol (130 mg) and placebo | Marked improvements (p < 0.01) in symptoms score and quality of life index and an increase in Qmax and a decrease in postvoid residual urinary volume |
| | Mendilaharsu et al. CCS lung cancer cases (n = 463) and hospitalized controls (n = 465). Duration: 3 years | Plant sterols intake, through food frequency questionnaire | Highest quartile intake of PS led to a 50% reduction in lung cancer risk (OR 0.29, 95% CI, 0.14–0.63) |
| | De Stefani et al. CCS gastric cancer cases (n = 120) and controls (n = 360). Duration: 2 years | Plant sterols, through food frequency questionnaire | Highest PS intake was inversely related to gastric cancer risk (OR 0.09, 95% CI, 0.02–0.32) |
| | McCann et al. CCS Ovarian cancer cases (n = 124) and controls (n = 360). Duration: 2 years | Plant sterols, through food frequency questionnaire | A lower risk was documented for women in the highest quintile of stigmasterol intake (OR 0.42, 95% CI, 0.20–0.87) |
| | Normen et al. CS colon (n = 620) and rectal (n = 344) cancer cases. Duration: 6.3 years | No association was found between PS intake and a lower cancer risk |
| **Gestational diabetes** | Li et al. RCT women with gestational diabetes mellitus (n = 206). Duration: 16 weeks | Margarine spread with (n = 102) or without (n = 104) PS | In PS-rich margarine spread, TAG (p = 0.017), TC (p = 0.032), and LDL-C (p = 0.027) levels were remarkably reduced, while HDL-C (p = 0.041) increased compared to baseline; also, fasting plasma glucose (p = 0.021) and serum insulin (p = 0.018) levels, insulin check index (p = 0.035), and β-cell function (p = 0.029) were also remarkably improved |
| | Gao et al. RCT women with gestational diabetes mellitus (n = 244). Duration: 13 weeks | Margarine spread with (n = 123) or without (n = 121) PS | PS-rich margarine spread had benefits on maternal diabetic symptoms, namely, in improving lipid composition (TC, p = 0.03; LDL, p = 0.02; HDL, p = 0.03) and glucose metabolism (p = 0.03), decreasing the incidence of neonatal complications |
| **Immunomodulation** | De Smet et al. CT healthy subjects (n = 14). Duration: 4 h | Snake with or without plant stanol esters (4 g/day) | No changes in genes profiles expression; T-cell function-involved pathways were downregulated in the jejunum |
| | Brull et al. RCT asthmatic patients (n = 58). Duration: 2 + 8 weeks | Plant stanol-rich soy-based yogurts (4 g stanols/day) or control yogurts | Higher antibody titters against hepatitis A virus (three and four weeks postvaccination, p = 0.037 and p = 0.030, respectively) and marked reductions in plasma total Ig-E, IL-1β (p < 0.05), and TNF-α (p < 0.05) levels in treated group |
| **Osteoporosis** | Granado-Lorencio et al. RCT postmenopausal women (n = 38). Duration: 4 weeks | β-cryptoxanthin (0.75 mg/day) and PS (1.5 g/day), single or combined | β-cryptoxanthin combined with PS led to marked changes in TC (p = 0.0047), HDL-C (p = 0.0057), and LDL-C (p = 0.0014) levels and bone turnover markers |

AST, aspartate aminotransferase; ALT, alanine aminotransferase; CT, clinical trial; CS, cohort study; CCS, case-control study; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; LDL-C, low-density lipoprotein cholesterol; PSs, phytosterols; RCT, randomized controlled trial; TC, total cholesterol; TAG, triacylglycerol; VLDL-C, very-low-density lipoprotein cholesterol.
blood and other tissues. For instance, at enterocytes level, it has been shown that PSs are absorbed, at least partially, by a Niemann-Pick 1C Like 1 transporter (NPC1L1)-mediated process (Borel and Desmarchelier, 2018). Thus, genetic variations in other genes, other than ABCG5/G8, may be involved in PS bioavailability modulation. The search for candidate gene associations was only focused on NPC1L1 and apolipoprotein E (APOE). First, it was confirmed that NPC1L1 is the single nucleotide polymorphisms that modulate PS bioavailability (Borel and Desmarchelier, 2018). In two studies, it was observed that, in subjects with apoE 3/4 or 4/4 alleles, the PS bioavailability was higher than in subjects with the apoE 3/3 allele. However, no biological mechanism has been proposed to explain how APOE can modulate PS absorption. This requires further research (Borel and Desmarchelier, 2018). Blanco-Morales et al. (Blanco-Morales et al., 2018) studied the action of adding galactooligosaccharides on sterols bioavailability in milk-fruit-based beverages, enriched with three plant sterols, after micellar GI digestion, and found that galactooligosaccharides addition did not affect the overall PS bioavailability.

**In Vivo Phytosterol Bioavailability**

Plant sterols are absorbed by many animals, with dogs, pigs, mice, rats, and sheep having approximately 10–20 times more sitosterol in serum and tissues than humans (∼5 μM) (DeHollander and Chevallier, 1969; Kuskis et al., 1976; Sugano et al., 1978; Strandberg et al., 1989; Miettinen et al., 1990; Morton et al., 1995; Shahzad et al., 2017).

In spite of structural similarities between cholesterol and PSs, their intake in the intestines of mammals is low. Overall, the PS absorption rates are 0.5%, 1.9%, 0.04%, and 0.16% for β-sitosterol, campesterol, sitostanol, and campestanol, respectively, compared to that of cholesterol (56%) (Ostlund et al., 2002; Ostlund, 2007). The low PS absorption when compared to cholesterol is attributed to their quick resecretion from intestinal cells back into the GI lumen through ABC G5 and ABC G8 transporters (Berge et al., 2000).

**Comparison of Preclinical and Clinical Findings**

Garcia-Llatas et al. (Garcia-Llatas et al., 2015) investigated for the first time preclinical and clinical PS bioavailability. Two fruit beverages based on milk were used; they were enriched with plant sterols and β-Cx, and their suitability was compared as phytosterol-rich food matrices and feasible effects on PS absorption (Garcia-Llatas et al., 2015). As main findings, the authors concluded that both *in vitro* (bioaccessibility determined from simulated gastrointestinal digestion) and *in vivo* (response in serum from individuals of an interventional study) models give similar results. In 36 postmenopausal women, Garcia-Llatas et al. (2015) stated that serum campesterol concentrations were notably raised (within 0.3–0.4 μg/ml) one month after beverage intake (1.5 g of PS/day). Thus, the authors concluded that the duration of PS-rich foods intake may affect serum levels and, consequently, their absorption. In the studies of Garcia-Llatas et al. (2015), Plana et al. (2008), and Casas-Agustench et al. (2012), with a duration of 28–42 days, it was established that the composition of bioavailable PS consumed with food included β-sitosterol (≥70%) and campesterol (≤10%). A longer investigation (up to 90 days) suggested that the bioavailability of both PS was equalized. After three months, the authors established lesser contents of β-sitosterol (37–50%) and higher contents of campesterol (20–30%) in the subject’s serum (Hernandez-Mijares et al., 2010).

**Phytosterol Bioavailability in Humans**

Ostlund et al. (2002) assessed the systemic intake of lecithin-emulsified Δ5-PS and phytosterols consumed with food and having isotopic labeling. The absorption of 600 mg of soybean Δ5 sterols added to subject’s standard breakfast was 0.512 ± 0.038% for sitosterol, 1.89 ± 0.27% for campesterol, 0.0441 ± 0.004% for sitostanol, and 0.155 ± 0.017% for campestanol. The authors also stated that the lack of a double bond in position five of the sterol cycle reduced absorption by more than eightfold. Indeed, the plasma concentration (t%) for stanols was achieved faster than that for delta5-sterols. Thus, it was stated that PS absorption proficiency is lower than previously stated. Indeed, both campesterol and sitostanol absorption were solely ~10% of the absorption of the corresponding Δ5 sterols, which indicates the dominant effect of the double bond saturation on absorption.

Several investigations have tested the serum PS concentrations after consuming PS-rich foods. These low-fat products included dairy products, such as low-fat milk and yogurt or fermented milk. All these studies were published by Ras et al., (2013) in a meta-analysis, including data from 41 studies, with a total of 2084 patients. The average PS dose added to food was 1.6 g/day (range: 0.3–3.2 g/day). Plasma sitosterol and campesterol concentrations were raised by on average 2.24 μmol/L (31%) and 5.00 μmol/L (37%), respectively, compared to control. The increase in both sitosterol and campesterol concentrations was due to the total PS and baseline doses used and the composition of the tested products. For PS doses of 2.0 g/day and 3.2 g/day, the increase for sitosterol and campesterol averaged 3.56 μmol/L and 7.64 μmol/L, respectively.

Baseline plasma sitosterol (6.9 μmol/L) and campesterol (13.1 μmol/L) concentrations stated by Ras et al., (2013) were also comparable to that previously published by Chan et al., (2006), who included data from 45 studies, where the average baseline concentrations of sitosterol and campesterol in the general population were 7.9 μmol/L and 14.2 μmol/L, respectively. According to Ras et al., (2013), changes in plasma PS concentration were linked to the PS dose daily consumed, and it was also established that the higher the dose, the greater the increase in both sitosterol and campesterol concentrations. The authors also reported that an even greater increase in plasma PS may be at doses >3.2 g/day.

Davidson et al. (Davidson et al., 2001) also assessed the PS content in the blood serum when 3, 6, and 9 g PS/day were added to food and found that the increase in serum PSs differed.

---

**Frontiers in Pharmacology | www.frontiersin.org January 2021 | Volume 11 | Article 599959**
slightly between the three doses used. However, even at the highest dose (9 g/day), the total absolute PS doses remained <2 mg/dl (∼50 µmol/L). Another work showed an increase in PS intake (1.25, 2.5, and 5 g/day) along with a minerals' mixture over three consecutive five-week periods (Tuomilehto et al., 2009). Serum sitosterol contents were raised dose-dependently, while campesterol did not. These results do not allow clear conclusions regarding dose-response relationships for plasma PS at higher doses when consumed with food (>3 g/day). The PS mixture composition and the source type also affected the magnitude of sitosterol and campesterol concentration increase in plasma. In separate studies, plasma PS concentrations were determined at different time points (De Jong et al., 2008), and differences in plasma concentrations of both sterols appeared to stabilize over time. For example, in the study of De Jong et al. (2008), the plasma concentrations of sitosterol and campesterol were the same after 45 and 85 weeks.

Salen et al. (1970) also found that oral PS bioavailability is extremely low (0.5–5%), depending on the sterols structure. In their study, β-sitosterol metabolism was compared with that of cholesterol in 12 patients who consumed β-sitosterol from a typical American diet. Plasma β-sitosterol concentration ranged from 0.30 mg/100 ml to 1.02 mg/100 ml, and plasma levels increased only slightly when the intake of β-sitosterol was significantly increased. With the consumption of food devoid of plant sterols, plasma and feces were quickly released from β-sitosterol. The concentration of esterified β-sitosterol in plasma was similar to that of cholesterol. However, the β-sitosterol esterification rate was lower than that of cholesterol (Salen et al., 1970). Thus, as studied patients do not have an endogenous β-sitosterol synthesis, the daily β-sitosterol turnover was equal to its daily intake after a meal. β-sitosterol absorption was 5% (or less) of daily intake, while that of cholesterol was 45–54%. Around 20% of β-sitosterol absorbed is metabolized to cholic and chenodeoxycholic acid, while the exceeding is excreted in the bile as a free sterol, with its elimination being faster than that of cholesterol (Salen et al., 1970).

Metabolic turnover, absolute oral bioavailability, clearance, and distribution volume of β-sitosterol were tested by Duchateau et al. in healthy volunteers (Duchateau et al., 2012) using [14C] β-sitosterol as an isotopic indicator at doses ranging from 3 µg to 4 µg, which was low enough as not to disturb diet-derived β-sitosterol kinetics. The absolute β-sitosterol bioavailability was extremely low (0.41%), with its metabolites not being detected in plasma (Duchateau et al., 2012). Thus, given the generally low PS bioavailability noticed in consumed food, several factors can influence this indicator (Racette et al., 2015) including the following:

1. PS type (i.e., plant sterol or stanol, esterified against nonesterified, steryl glycosides, and PS solubility). A direct correlation between chemical structure (saturation degree of the sterol ring and side-chain length) and low absorption rate has been stated. Campesterol (with a methyl group) has higher absorption rates than β-sitosterol (with an ethyl group) (Bradford and Awad, 2007; Miras-Moreno et al., 2016).

2. Chemical structure of PSs (e.g., sitosterol, campesterol, stigmasterol, brassicasterol, Δ-5-avenasterol, sitostanol, or campestanol).

3. PS source (e.g., soybean oil, corn oil, or shea nut oil).

4. Processing (e.g., refining or hydrogenation). Refining and hydrogenation of vegetable oils reduce both the content of free sterols and sterols amount in oils (Phillips et al., 2002; Racette et al., 2015).

5. Food preparation (e.g., boiling) (Normen et al., 1999; Racette et al., 2015).

6. Other nutrients (e.g., fiber) and aspects related to the food item (i.e., food matrix, injected dose, administration frequency and time, delivery method (emulsifiers use soy lecithin), and surfactants) (Berger et al., 2004).

7. Genetic factors (Berger et al., 2004).

CONCLUSIONS

PSs are plant-derived steroids. Over 250 PSs have been isolated, and each plant species contains a characteristic phytosterol composition. A wide number of researches have reported that PSs possess a wide variety of interesting pharmacological properties, including anti-inflammatory, antioxidant, antidiabetic, chemopreventive, and antiatherosclerotic effects. Nonetheless, PS bioavailability is a limiting aspect that may be affected by multiple factors, such as the type, source, processing, preparation, delivery method, food matrix, dose, time of administration into the body, and genetic factors, and there exists an intercorrelation between low absorption rates and their chemical structure. Thus, further studies are needed to ensure a more in-depth understanding of the multiple potentialities of PSs and to design upcoming strategies to overcome the currently identified bioavailability-related gaps.

AUTHOR CONTRIBUTIONS

All authors contributed equally to this work. JS-R, WZ, FS, WK, and NCM critically reviewed the manuscript. All the authors read and approved the final manuscript. All authors have read and agreed to the published version of the manuscript.

ACKNOWLEDGMENTS

NCM acknowledges the Portuguese Foundation for Science and Technology under the Horizon 2020 Program (PTDC/PSI-GER/28076/2017).
D’Hollander, F., and Chevallier, F. (1969). [Qualitative and quantitative estimation of free and esterified sterols in whole rat and in 23 of its tissues and organs]. Biochim. Biophys. Acta 176, 146–162.

Daniel, P. T., Wieder, T., Sturm, I., and Schulze-Osthoff, K. (2001). The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 15, 1022–1032. doi:10.1038/sj.leu.2402169

Davidson, M. H., Maki, K. C., Umporowicz, D. M., Ingram, K. A., Dickin, M. R., Schaefer, E., et al. (2001). Safety and tolerability of esterified phytosterols administered in reduced-fat spread and salad dressing to healthy adult men and women. J. Am. Coll. Nutr. 20, 307–319. doi:10.1080/07315724.2001.10791951

De Jong, A., Plat, J., Luitjohann, D., and Mensink, R. P. (2008). Effects of long-term plant sterol or stanol ester consumption on lipid and lipoprotein metabolism in subjects on statin treatment. Br. J. Nutr. 100, 937–941. doi:10.1017/s0007114508966113

De Jongh, S., Vissers, M. N., Rol, P., Bakker, H. D., Kastelein, J. J., and Stroes, E. S. (2003). Plant sterols lower LDL cholesterol without improving endothelial related pathways in the jejunum of healthy volunteers. Br. J. Nutr. 113, 794–802. doi:10.1017/s000711451000350X

De Stefani, E., Bochkov, R., Ronco, A. L., Brennan, P., Deneo-Pellegrini, H., Carzoglio, J. C., et al. (2000). Absolute oral bioavailability and metabolic turnover of β-sitosterol in healthy subjects. Drug Metab. Dispos. 28, 2026–2030. doi:10.1124/dmd.112.046623

Dutta, P. C. (2003). Phytosterols as functional food components and nutraceuticals. Boca Raton, FL: CRC Press.

Escurriol, V., Cofán, M., Moreno-Iribas, C., Larrañaga, N., Martínez, C., Navarro, F. A., et al. (2010). Plant sterols and risk of stomach cancer: a case-control study in Uruguay. Br. J. Nutr. 100, 937–941. doi:10.1017/S000711451000350X

Gao, F., Wang, G., Wang, L., and Guo, N. (2017). Phytosterol nutritional science and technology. Boca Raton, FL: CRC Press.

Granado-Lorencio, F., Lagarda, M. J., García-López, F. J., Sánchez-Siles, L. M., Blanco-Navarro, I., Alegria, A., et al. (2014). Effect of β-cryptoxanthin plus phytosterols on cardiovascular risk and bone turnover markers in post-menopausal women: a randomized crossover trial. Nutr. Metabol. Cardiovasc. Dis. 24, 1990–1996. doi:10.1016/j.numecd.2014.04.013

Gupta, A. K., Savopulos, C. G., Ahuja, J., and Hatzitolios, A. I. (2011). Role of phytosterols in lipid-lowering: current perspectives. QJM 104, 301–308. doi:10.1093/qjmed/hcr077

Heinemann, T., Leiss, O., and Von Bergmann, K. (1986). Effect of low-dose sitostanol on serum cholesterol in patients with hypercholesterolemia. Atherosclerosis 61, 219–223. doi:10.1016/0952-829X(86)90141-3

Herbst, R. S., Eckhardt, S. G., Kurzrock, R., Ebbinghaus, S., O’dwyer, P. J., Gordon, M. S., et al. (2010). Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J. Clin. Oncol. 28, 2883–2886. doi:10.1200/JCO.2009.25.1991

Hernández-Muiàres, A., Barúls, C., Rocha, M., Morillas, C., Martínez-Trigueros, M. L., Víctor, V. M., et al. (2010). Effects of phytosterol ester-enriched low-fat milk on serum lipoprotein profile in mildly hypercholesterolaemic patients are not related to dietary cholesterol or saturated fat intake. Br. J. Nutr. 104, 1018–1025. doi:10.1017/S0007114510001686

Hwang, S. L., Kim, H. N., Jung, H. H., Kim, J. E., Choi, D. K., Hur, J. M., et al. (2008). Beneficial effects of beta-sitosterol on glucose and lipid metabolism in IL-6 myotube cells are mediated by AMP-activated protein kinase. Biochem. Biophys. Res. Commun. 377, 1253–1258. doi:10.1016/j.bbrc.2008.10.136

Iaccarino, N., Amato, J., Pagano, B., Di Porzio, A., Micucci, M., Boldelli, L., et al. (2019). Impact of phytosterols on liver and dural calci metabolism in experimental murine colitis model: an explorative study. J. Enzym. Inhib. Med. Chem. 34, 1041–1050. doi:10.1080/14756366.2019.1611802

Ikeda, I., and Sugano, M. (1978). Comparison of absorption and metabolism of beta-sitosterol and beta-sitostanol in rats. Atherosclerosis 30, 227–237. doi:10.1016/0021-9150(78)90049-7

Ikeda, I., Tanaka, K., Sugano, M., Vahouny, G. V., and Gallo, L. L. (1988). Inhibition of cholesterol absorption in rats by plant sterols. J. Lipid Res. 29, 1573–1582.

Imran, M., Salehi, S., Sharifiz-Rad, J., Gondal, T. A., Saeed, F., Imran, A., et al. (2019). Kaempferol: a key emphasis to its anticancer potential. Molecules 24, 2277. doi:10.3390/molecules24122277

Jaksul, L., Vissers, M. N., Rodenburg, J., Wiegman, A., Trip, M. D., and Kastelein, J. J. (2006). Plant stanols do not restore endothelial function in prepubertal children with familial hypercholesterolemia despite reduction of low-density lipoprotein cholesterol levels. J. Pediatr. 148, 495–500. doi:10.1016/j.jpeds.2005.11.023

Javanmardi, M. A., Mohammad Shahi, M., Seyedian, S. S., and Haghhighizadeh, M. H. (2018). Effects of phytosterol supplementation on serum levels of lipid profiles, liver enzymes, inflammatory markers, adiponectin, and leptin in patients affected by nonalcoholic fatty liver disease: a double-blind, placebo-controlled, randomized clinical trial. J. Am. Coll. Nutr. 1–8 [Epub ahead of print]. doi:10.1080/07315724.2018.1466739

Jessup, W., Herman, A., and Chapman, J. (2008). Phytosterols in cardiovascular disease:innocuous dietary components,or accelerators of atherosclerosis?. Future Lipidol. 3, 301–310. doi:10.2217/flp.07.53

Jiang, L., Zhao, X., Xu, J., Li, C., Yu, Y., Wang, W., et al. (2019). The protective effect of dietary phytosterols on cancer risk: a systematic meta-analysis. J. Oncol 2019, 7497958. doi:10.1155/2019/7497958

Jones, P. J., and Abu-Ossie, S. S. (2009). Phytosterols as functional food ingredients: linkages to cardiovascular disease and cancer. Curr. Opin. Clin. Nutr. Metab. Care 12, 147–151. doi:10.1097/mcco.0b013e328326770f

Jones, P. J., Vanstone, C. A., Raeini-Sarjaz, M., and St-Onge, M. P. (2013). Phytosterols in low- and nonfat beverages as part of a controlled diet fail to lower plasma lipid levels. J. Lipid Res. 44, 1713–1719. doi:10.1194/jlr.M300089-JLR200

Katan, M. B., Grundy, S. M., Jones, P., Law, M., Miettinen, T., Paoletti, R., et al. (2003). Efficacy and safety of plant stanols and steres in the management of blood cholesterol levels. Mayo Clin. Proc. 78, 965–978. doi:10.4065/78.8.985

Ketomaki, A., Gylling, H., and Miettinen, T. A. (2004). Effects of plant sterol and stanol esters on serum phytosterols in a family with familial hypercholesterolemia including a homozygous subject. J. Lab. Clin. Med. 143, 255–262. doi:10.1016/j.lab.2003.11.007

Klippel, K. F., Hilf, D. M., and Schipp, B. (1997). A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. Br. J. Urol. 80, 427–432.
Phytosterols

Racette, S. B., Lin, X., Ma, L., and Ostlund, R. E., Jr. (2015). Natural dietary phytosterols. J. AOAC Int. 98, 679–684. doi:10.5740/jaoacint.SGERacette

Rajavel, T., Mohankumar, R., Archunan, G., Ruckmani, K., and Devi, K. P. (2017). Beta sitosterol and Daucosterol (phytosterols identified in Grewia tilaifolia) perturbs cell cycle and induces apoptotic cell death in A549 cells. Sci. Rep. 7, 3418. doi:10.1038/s41598-017-03511-4

Ras, R. T., Hiemstra, H., Lin, Y., Vermeer, M. A., Duchateau, G. S., and Trautwein, E. A. (2013). Consumption of plant sterol-enriched foods and effects on plasma plant sterol concentrations—a meta-analysis of randomized controlled studies. Atherosclerosis 230, 336–346. doi:10.1016/j.atherosclerosis.2013.08.012

Rideout, T. C., Marinangeli, C. P., and Harding, S. V. (2015a). Triglyceride-lowering response to plant sterol and stanol consumption. J. AOAC Int. 98, 707–715. doi:10.5740/jaoacint.SGERideout

Rideout, T. C., Movsesian, C., Tsai, Y. T., Iqbal, A., Raslawsky, A., and Patel, M. S. (2015b). Maternal phytosterol supplementation during pregnancy and lactation modulates lipid and lipoprotein response in offspring of apoE-deficient mice. J. Nutr. 145, 1728–1734. doi:10.3945/jn.115.215061

Rideout, T. C., Ramprashat, V., Griffin, J. D., Browne, R. W., Harding, S. V., and Jones, P. J. (2014). Phytosterols protect against diet-induced hyperglycemia in Syrian golden hamsters. Lipids Health Dis. 13, 3. doi:10.1186/s12931-013-0135-5

Rubis, B., Paszel, A., Kaczmarek, M., Rudzinska, M., Jelen, H., and Rybczynska, M. (2008). Beneficial or harmful influence of phytosterols on human cells? Br. J. Nutr. 100, 1183–1191. doi:10.1017/S0007114508002123

Rui, X., Wenfang, L., Jing, C., Meng, C., Chengcheng, D., Jiqu, X., et al. (2017). Neuroprotective effects of phytosterol esters against high cholesterol-a potential risk factor for coronary heart disease. Metab. Clin. Exp. 145, 1728. doi:10.1016/j.bbi.2017.08.012

Schiepers, O. J., De Groot, R. H., Van Boxtel, M. P., Jolles, J., De Jong, A., Rideout, T. C., Marinangeli, C. P., and Harding, S. V. (2015a). Triglyceride-lowering properties of plant sterols and stanols are associated with decreased lipid and high carbohydrate diet induced atherosclerosis. Atherosclerosis 230, 336–346. doi:10.1016/j.atherosclerosis.2013.08.012

Salehi et al. Phytosterols

San Mauro-Martín, I., Blumenfeld-Olivares, J. A., Garicano-Vilar, E., Cuadrado, E. A. (2013). Consumption of plant sterol-enriched foods and effects on plasma plant sterols. J. Nutr. 143, 1373. doi:10.3945/jn.112.142398

Sugano, M., Morioka, H., Kida, Y., and Ikeda, I. (1978). The distribution of dietary phytosterols in the mouse. Metab. Brain Dis. 3, 3390. doi:10.1023/a:10217492804133

Tuomilehto, J., Tikkanen, M. J., Högström, P., Keinänen-Kiukaanniemi, S., Piironen, V., Toivo, J., et al. (2009). Safety assessment of common foods enriched with natural nonesterified plant sterols. Eur. J. Clin. Nutr. 63, 684–691. doi:10.1038/ejcn.2008.11

Van Rensburg, S. J., Daniels, W. M., Van Zyl, J. M., and Taljaard, J. J. (2000). A vascular effects of diet supplementation with plant sterols. J. Cardiovasc. Risk 7, 145–1728. doi:10.1016/s1079-6114(00)00058-5

Wadikar, D. D., Lakshmi, L., and Patki, P. E. (2017). Phytosterols: an appraisal of potential countermeasures for high cholesterol disease in women. J. Am. Coll. Cardiol. 62, 1553–1561. doi:10.1016/j.jacc.2017.03.074

Windler, E., Zyrax, B. C., Kuipers, F., Linseisen, J., and Boehm, H. (2009). Association of plasma phytosterol concentrations with incident coronary heart disease Data from the CORA study, a case-control study of coronary artery disease in women. Atherosclerosis 203, 284–290. doi:10.1016/j.atherosclerosis.2008.06.014

Xu, Z., Le, K., and Moghaddasian, M. H. (2008). Long-term phytosterol treatment alters gene expression in the liver of apoE-deficient mice. J. Nutr. Biochem. 19, 545–554. doi:10.1016/j.jnutbio.2007.06.012

Zaklo–Szody, M. (2015). Phytosterols in type 2 diabetes and obesity – molecular mechanisms of action. Research Signpost.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Salehi, Quispe, Sharifi-Rad, Cruz-Martins, Nigam, Mishra, Konovalov, Orobinskaya, Abu-Reidah, Zam, Sharopov, Venmeri, Capasso, Kakula-Koch, Wawruszak and Koch. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.